RAPAMYCIN
MODERATE
▲ +4 papers · 7d
METFORMIN
MODERATE
▲ +2 papers · 7d
GLP-1 RA
STRONG
▲ +11 papers · 7d
SENOLYTICS
EMERGING
▼ −1 retraction
NMN
EMERGING
▲ +1 RCT · 7d
ACARBOSE
MODERATE
SGLT2i
STRONG
▲ +3 meta · 30d
RAPAMYCIN
MODERATE
▲ +4 papers · 7d
METFORMIN
MODERATE
▲ +2 papers · 7d
GLP-1 RA
STRONG
▲ +11 papers · 7d
SENOLYTICS
EMERGING
▼ −1 retraction
NMN
EMERGING
▲ +1 RCT · 7d
ACARBOSE
MODERATE
SGLT2i
STRONG
▲ +3 meta · 30d
Vol.
IV
· No.
19
Thursday, May 14, 2026
Issue:
Spring · 2026
Established · MMXXVI
Geroevidence
— The evidence base for longevity medicine —
Indexed by
PubMed
·
CTG
·
Cochrane
Editorial team ·
geroevidence.com
Subscription ·
app.geroevidence.com
Home
Interventions
Evidence
Blog
About
Pricing
Sign in
Start free trial →
Geroevidence
·
Editorial desk
·
Editorial
Editorial
From the Geroevidence editorial team.
2 articles in this category
·
← All categories
§ Editorial · 2 articles
Why Geroevidence exists
A statement of purpose — what we are building, who it is for, and what we will never claim to be.
May 6, 2026 · 5 min read
How Geroevidence came to be
The origin of a clinical evidence platform — built not by a physician, but by someone who works inside the healthcare system and grew tired of watching good science reach clinicians poorly.
May 5, 2026 · 6 min read